Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients with PDAC have mutations in KRAS, which unfortunately remains an ineffectual target. Our strategy here is to target KRAS downstream effectors PI3K and mTOR. In this study,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Ning, Changwen, Liang, Min, Liu, Shuang, Wang, Guan, Edwards, Holly, Xia, Yang, Polin, Lisa, Dyson, Gregory, Taub, Jeffrey W., Mohammad, Ramzi M., Azmi, Asfar S., Zhao, Lijing, Ge, Yubin
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2017
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546481/
https://ncbi.nlm.nih.gov/pubmed/28574828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17869
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk